• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Subcutaneous Opdivo Similarly Effective, Safe as IV for Advanced ccRCC

by MM360 Staff | Apr 16, 2025 | Uncategorized

Source: CureToday articles Subcutaneous Opdivo showed comparable effectiveness, safety and tolerability to IV Opdivo in advanced clear cell renal cell carcinoma. Read More

Understanding How to Advance Immunotherapy Strategy Models in Melanoma

by MM360 Staff | Apr 16, 2025 | Uncategorized

Source: CureToday articles Melanoma is a key cancer type for developing and testing immunotherapies prior to broader clinical application across other malignancies. Read More

Erleada Reduces Risk of Death in Metastatic Prostate Cancer Subset

by MM360 Staff | Apr 16, 2025 | Uncategorized

Source: CureToday articles Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate cancer. Read More

Understanding Esophageal Cancer: Early Signs, Risks and Key Insights

by MM360 Staff | Apr 16, 2025 | Uncategorized

Source: CureToday articles Dr. Nataliya Uboha sat down to discuss the early warning signs of esophageal cancer, as well as important key takeaways for those with the disease. Read More

Bexmarilimab Plus Vidaza Elicit Responses in Myelodysplastic Syndromes

by MM360 Staff | Apr 16, 2025 | Uncategorized

Source: CureToday articles Treatment with bexmarilimab and Vidaza elicited high overall response rates in both frontline and relapsed/refractory higher-risk myelodysplastic syndrome. Read More

Bria-IMT Combo Outperforms Other Metastatic Breast Cancer Treatments

by MM360 Staff | Apr 16, 2025 | Uncategorized

Source: CureToday articles Bria-IMT plus check point inhibitors had a median overall survival which outperformed that of antibody-drug conjugates in HR+ metastatic breast cancer. Read More
« Older Entries
Next Entries »

Recent Content

  • “Chillin’ Out” and Finding Our Cancer Community
  • AAN 2025: Pharmacists Play Critical Role in Monitoring, Managing Lecanemab Therapy
  • Bavencio Maintains Bladder Cancer Benefit in Patients with Diabetes
  • Risk of lymphoid malignancy associated with cancer predisposition genes
  • Large-scale human myeloma cell line small molecule compound screen dataset
  • Optimal Jakafi Dosing Associated With Improved Outcomes in Myelofibrosis
  • PCV10 Elicits Durable Immune Response in T2D, Though Response Remains Inferior to Non-Diabetics
  • AAN 2025: Insights on Pediatric Multiple Sclerosis Treatment and Management
  • Illuminating Compassion in Cancer Care
  • Renowned Breast Cancer Physician-Scientist Dr. Hope S. Rugo to Lead City of Hope’s Women’s Cancers Program
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT